Viatris Inc. (VTRS)
| Bid | 10.8 |
| Market Cap | 12.95B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -14.86 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 10.9 |
| Volume | 5,196,388 |
| Avg. Volume (20D) | 9,194,979 |
| Open | 10.78 |
| Previous Close | 10.80 |
| Day's Range | 10.74 - 10.87 |
| 52-Week Range | 9.93 - 13.62 |
| Beta | undefined |
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, end...
Analyst Forecast
According to 3 analyst ratings, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 29.03% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Viatris: Looking At High Free Cash Flow Yield As Business StabilizesWe have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that ...
